Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jan 11, 2020
Date Accepted: Feb 21, 2020
Date Submitted to PubMed: Jan 11, 2020

The final, peer-reviewed published version of this preprint can be found here:

Efficacy of the Digital Therapeutic Mobile App BioBase to Reduce Stress and Improve Mental Well-Being Among University Students: Randomized Controlled Trial

Ponzo S, Morelli D, Kawadler JM, Hemmings NR, Bird G, Plans D

Efficacy of the Digital Therapeutic Mobile App BioBase to Reduce Stress and Improve Mental Well-Being Among University Students: Randomized Controlled Trial

JMIR Mhealth Uhealth 2020;8(4):e17767

DOI: 10.2196/17767

PMID: 31926063

PMCID: 7171562

Efficacy of the Digital Therapeutic Mobile App “BioBase” to Reduce Stress and Improve Mental Wellbeing Among University Students: a Randomized Controlled Trial

  • Sonia Ponzo; 
  • Davide Morelli; 
  • Jamie M Kawadler; 
  • Nicola Rose Hemmings; 
  • Geoffrey Bird; 
  • David Plans

ABSTRACT

Background:

UK university students are experiencing increasing levels of anxiety. A programme designed to increase awareness of one’s present levels of wellbeing and suggest personalized health behaviours may reduce anxiety and improve mental wellbeing in students. The efficacy of a digital version of such a programme, providing biofeedback and therapeutic content based on personalized wellbeing metrics, is reported here.

Objective:

The aim of this study was to test the efficacy and sustained effects of using a mobile app (BioBase) and paired wearable device (BioBeam), compared to a wait-list control group, on anxiety and wellbeing in university students with elevated levels of anxiety and stress.

Methods:

The study employed a randomized, wait-list controlled, trial with assessments at baseline, 2-weeks, post-intervention (4 weeks), and at follow-up (6 weeks). Participants were eligible if they were current full-time undergraduate students and (1) at least 18 years of age, (2) scored >14 points on the DASS-21 stress subscale or > 7 points on the DASS-21 anxiety subscale, (3) owned an iOS smartphone, (4) did not have any previous psychiatric or neurological conditions, (6) were not pregnant at the time of testing, and (7) were able to read and understand English. Participants were encouraged to use BioBase daily and complete at least one course of therapeutic content. A p value ≤.05 was considered statistically significant.

Results:

We found that a 4-weeks intervention with the BioBase programme significantly reduced anxiety and increased perceived wellbeing, with sustained effects at a 2-weeks follow-up. Furthermore, a significant reduction in depression levels was found following 4-weeks usage of Biobase.

Conclusions:

This study shows the efficacy of a biofeedback digital intervention in reducing self-reported anxiety and increasing perceived wellbeing in UK university students. Results suggest that digital mental health interventions could constitute a novel approach to treat stress and anxiety in students, which could be combined, or integrated with, existing therapeutic pathways. Clinical Trial: https://osf.io/2w5sy/


 Citation

Please cite as:

Ponzo S, Morelli D, Kawadler JM, Hemmings NR, Bird G, Plans D

Efficacy of the Digital Therapeutic Mobile App BioBase to Reduce Stress and Improve Mental Well-Being Among University Students: Randomized Controlled Trial

JMIR Mhealth Uhealth 2020;8(4):e17767

DOI: 10.2196/17767

PMID: 31926063

PMCID: 7171562

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.